J Pediatr Hematol Oncol. 2025 Jul 1. doi: 10.1097/MPH.0000000000003080. Online ahead of print.
ABSTRACT
BACKGROUND: Ependymomas of the posterior fossa type A (PF-A) with a combined chromosome 1q gain and 6q loss are associated with an extremely high risk of recurrence and a very poor outcome.
OBSERVATIONS: We report the case of a 4-year-old girl who received adjuvant oral etoposide for 1 year after conventional treatment (surgery and focal radiation). The patient remains in clinical and radiologic remission 2.5 years post-diagnosis.
CONCLUSIONS: This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial.
PMID:40591907 | DOI:10.1097/MPH.0000000000003080
